Section Arrow
Quote
TRAX.NASDAQ
- First Tracks Biotherapeutics Inc.
Quotes are at least 15-min delayed:2026/09/04 09:34 EDT
Regular Hours
Last
 42
-0.51 (-1.20%)
Day High 
42 
Prev. Close
42.51 
1-M High
49.9114 
Volume 
6.90K 
Bid
40.3
Ask
41.95
Day Low
40.38 
Open
41.06 
1-M Low
39.83 
Market Cap 
1.52B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 43.31 
20-SMA 44.11 
50-SMA 37.69 
52-W High 49.9114 
52-W Low 14.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.71/-3.83
Enterprise Value
1.53B
Balance Sheet
Book Value Per Share
4.72
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IMRNImmuron Limited1.9+0.79+71.17%-- 
CMNDClearmind Medicine Inc.1.46-0.24-14.12%-- 
CABACabaletta Bio3.51+0.03+0.86%-- 
MRNAModerna148.45-0.42-0.28%-- 
RAREUltragenyx Pharmaceutical15.7399+0.8899+5.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101,a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.